Table 6.

Intracytoplasmatic cytokine detection in HCMV- or CA-specific TCCs stimulated in vitro with PMA and ionomycin

Patient/control no.
Total TCCs, no.*
TH1-dominant TCCs, no.
TH2-dominant TCCs, no.
NP-TH TCCs, no.
HCMV-specific TCC     
CBT-sib      
2, 12-15 mo after BMT   1   1†  0   0  
CBT-ud      
12, 12-15 mo after BMT   3   1   2   0  
Control      
17   2   0   1   1  
18   1   0   0   1  
19   6   4   1   1  
CA-specific TCC     
CBT-sib      
3, 3-5 mo after BMT   15   8‡  2   5  
4, 3-5 mo after BMT   7   7§  0   0  
5, 12-15 mo after BMT   9   8   1   0  
CBT-ud      
13, 3-5 mo after BMT   12   0   12   0  
Control      
17   8   2   2   4  
18   6   1   4   1  
19
 		 6
 		 2
 		 2
 		 2
 
Patient/control no.
Total TCCs, no.*
TH1-dominant TCCs, no.
TH2-dominant TCCs, no.
NP-TH TCCs, no.
HCMV-specific TCC     
CBT-sib      
2, 12-15 mo after BMT   1   1†  0   0  
CBT-ud      
12, 12-15 mo after BMT   3   1   2   0  
Control      
17   2   0   1   1  
18   1   0   0   1  
19   6   4   1   1  
CA-specific TCC     
CBT-sib      
3, 3-5 mo after BMT   15   8‡  2   5  
4, 3-5 mo after BMT   7   7§  0   0  
5, 12-15 mo after BMT   9   8   1   0  
CBT-ud      
13, 3-5 mo after BMT   12   0   12   0  
Control      
17   8   2   2   4  
18   6   1   4   1  
19
 		 6
 		 2
 		 2
 		 2
 
*

Number of TCCs tested.

†

TCCs of recipient origin.

‡

One of 8 TCCs was of recipient origin.

§

Five of 7 TCCs were of recipient origin.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal